[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Opioid Overdose - Pipeline Insight, 2019

October 2019 | 60 pages | ID: O94811A10EE4EN
DelveInsight

US$ 1,000.00 US$ 1,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

'Opioid Overdose - Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Overdose pipeline landscape is provided which includes the disease overview and Opioid Overdose treatment guidelines. The assessment part of the report embraces, in depth Opioid Overdose commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Overdose collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Opioid Overdose Understanding

According to World Health Organization, Opioids are substances derived from the opium poppy, or synthetic analogues with similar effects. Examples are morphine, heroin, tramadol, oxycodone and methadone. An overdose occurs when larger quantities than physically tolerated are taken, resulting in central nervous system and respiratory depression, miosis, and apnea, which can be fatal if not treated rapidly. An opioid overdose can be identified by a combination of three signs and symptoms referred to as the “opioid overdose triad”. The symptoms of the triad are: pinpoint pupil, unconsciousness, and respiratory depression. Opioids have the potential to cause substance dependence that is characterized by a strong desire to take opioids, impaired control over opioid use, persistent opioid use despite harmful consequences, a higher priority given to opioid use than to other activities and obligations, increased tolerance, and a physical withdrawal reaction when opioids are discontinued. The signs and symptoms of an opioid overdose include, the person's face is extremely pale and/or feels clammy to the touch, body goes limp, fingernails or lips have a purple or blue color, vomiting, are unable to speak, and breathing or heartbeat slows or stops.

Opioid Overdose Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Opioid Overdose targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Opioid Overdose pipeline report covers 12+ companies. Some of the key players include Orexo (OX124), Adapt Pharma (AP 003) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Opioid Overdose Analytical Perspective by DelveInsight
  • In-depth Opioid Overdose Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Opioid Overdose Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

SCOPE OF THE REPORT
  • The Opioid Overdose report provides an overview of therapeutic pipeline activity for Opioid Overdose across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Opioid Overdose therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Opioid Overdose Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Opioid Overdose
REASONS TO BUY
  • Establish a comprehensive understanding of the current pipeline scenario across Opioid Overdose to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Opioid Overdose R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Opioid Overdose in licensing and out licensing strategies by identifying prospective partners with progressing projects for Opioid Overdose to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. OPIOID OVERDOSE

2.1. Opioid Overdose Disease Overview
2.2. Opioid Overdose History
2.3. Opioid Overdose Symptoms
2.4. Opioid Overdose Causes
2.5. Opioid Overdose Pathophysiology
2.6. Opioid Overdose Diagnosis
  2.6.1. Diagnostic Guidelines

3. OPIOID OVERDOSE CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. OPIOID OVERDOSE- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Opioid Overdose companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Opioid Overdose Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Opioid Overdose Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. OPIOID OVERDOSE PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. OPIOID OVERDOSE-PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. OX124- Orexo
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
  6.1.2. AP 003- Adapt Pharma
    6.1.2.1. Product Description
      6.1.2.1.1. Product Overview
      6.1.2.1.2. Mechanism of Action
    6.1.2.2. Research and Development
      6.1.2.2.1. Clinical Studies
        6.1.2.2.1.1. Detailed Study Description
        6.1.2.2.1.2. Study Results
        6.1.2.2.1.3. Clinical Trials: Tabular View
    6.1.2.3. Product Development Activities
      6.1.2.3.1. Tabulated Product Summary
        6.1.2.3.1.1. General Description Table

7. RECENT TECHNOLOGIES

8. OPIOID OVERDOSE KEY COMPANIES

8.1. kaleo
8.2. Adamis Pharmaceuticals
8.3. Adapt Pharma
8.4. Recordati
8.5. Amphastar Pharmaceuticals
8.6. Opiant Pharmaceuticals
8.7. Hikma Pharmaceuticals
8.8. Orexo
8.9. Altovida
8.10. AntiOp
8.11. Mucodel
8.12. VDM Biochemicals

9. OPIOID OVERDOSE KEY PRODUCTS

9.1. Naloxone injection
9.2. APC 6000
9.3. AP
9.4. Methadone
9.5. Naloxone intranasal
9.6. Intranasal nalmefene
9.7. Naloxone intranasal spray
9.8. OX
9.9. ALT-022
9.10. Intrasal naltrexone
9.11. Naloxone gel
9.12. VDM

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. OPIOID OVERDOSE- UNMET NEEDS

12. OPIOID OVERDOSE- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Opioid Overdose Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Opioid Overdose companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Opioid Overdose Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

kaleo
Adamis Pharmaceuticals
Adapt Pharma
Recordati
Lightlake Therapeutics
Amphastar Pharmaceuticals
Opiant Pharmaceuticals
Hikma Pharmaceuticals
Orexo
Altovida
AntiOp
Mucodel
VDM Biochemicals



More Publications